Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
